Diagnosis, treatment and clinical perspectives of acromegaly

References

• Medvei VC. A history of endocrinology. Lancaster, England: MTP Press Limited; 1982.
   Google Scholar
• Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717–797.
   PubMed Web of Science ®Google Scholar
• Zadik Z, Chalew SA, McCarter RJ Jr, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab. 1985;60(3):513–516.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Veldhuis J. Growth hormone dynamics in healthy adults are related to age and sex, and strongly dependent on body mass index. Neuroendocrinology. 2015. DOI:10.1159/000438904.
   Google Scholar
• Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74.
   PubMed Web of Science ®Google Scholar
• Manolopoulou J, Alami Y, Petersenn S, et al. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant. Clin Chem. 2012;58(10):1446–1456.
   PubMed Web of Science ®Google Scholar
• Friedrich N, Wolthers OD, Arafat AM, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99(5):1675–1686.
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5): 1712–1721.
   PubMed Web of Science ®Google Scholar
• Cox HD, Lopes F, Woldemariam GA, et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin Chem. 2014;60(3):541–548.
   PubMed Web of Science ®Google Scholar
• Kay R, Halsall DJ, Annamalai AK, et al. A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2013;78(3):424–430.
   PubMed Web of Science ®Google Scholar
• Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73(5):233–240.
   PubMed Web of Science ®Google Scholar
• Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980;12(1):71–79.
   PubMed Web of Science ®Google Scholar
• Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26(4):481–512.
   PubMed Web of Science ®Google Scholar
• Trepp R, Stettler C, Zwahlen M, et al. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien). 2005;147(3):243–251.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89(6): 2789–2796.
   PubMed Web of Science ®Google Scholar
• Valdemarsson S, Ljunggren S, Bramnert M, et al. Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly. J Intern Med. 2000;247(6):640–650.
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab. 2008;93(6):2035–2041.
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–446.
   PubMed Web of Science ®Google Scholar
• Ritchie CM, Atkinson AB, Kennedy AL, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J. 1990;59(1):55–62.
   PubMedGoogle Scholar
• Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary. 2015. DOI:10.1007/s11102-015-0655-4.
   PubMedGoogle Scholar
• Rosario PW, Calsolari MR. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary. 2012;15(2):179–183.
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf). 2008;69(3):432–435.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–3148.
   PubMed Web of Science ®Google Scholar
• Ghazi AA, Amirbaigloo A, Dezfooli AA, et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine. 2013;43(2):293–302.
   PubMed Web of Science ®Google Scholar
• Crowley RK, Al-Derazi Y, Lynch K, et al. Acromegaly associated with gangliocytoma. Ir J Med Sci. 2012;181(3):353–355.
   PubMed Web of Science ®Google Scholar
• Cordero RA, Barkan AL. Current diagnosis of acromegaly. Rev Endocr Metab Disord. 2008;9(1):13–19.
   PubMed Web of Science ®Google Scholar
• Asa SL, Scheithauer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab. 1984;58(5):796–803.
   PubMed Web of Science ®Google Scholar
• Ezzat S, Ezrin C, Yamashita S, et al. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer. 1993;71(1):66–70.
   PubMed Web of Science ®Google Scholar
• Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Bidlingmaier M et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med. 2000;342(25):1871–1876.
   PubMed Web of Science ®Google Scholar
• Ozkaya M, Sayiner ZA, Kiran G, et al. Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma. Wien Klin Wochenschr. 2015;127:491–493. DOI:10.1007/s00508-015-0775-x.
   PubMed Web of Science ®Google Scholar
• Biswal S, Srinivasan B, Dutta P, et al. Acromegaly caused by ectopic growth hormone: a rare manifestation of a bronchial carcinoid. Ann Thorac Surg. 2008;85(1):330–332.
   PubMed Web of Science ®Google Scholar
• Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100(1):41–52.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation. 1999;99(11): 1426–1434.
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003;58(2):169–176.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Galderisi M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7): 2639–2646.
   PubMed Web of Science ®Google Scholar
• Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab. 2002;87(7):3097–3104.
   PubMed Web of Science ®Google Scholar
• Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13(1): 51–56.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Colao A, Ferone D, et al. Effect of growth hormone on cardiac function. Horm Res. 1997;48(Suppl 4): 38–42.
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Bax JJ, Roelfsema F, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res. 2006;16(2):101–107.
   PubMed Web of Science ®Google Scholar
• Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89(1):71–75.
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf). 2005;63(4):470–476.
   PubMed Web of Science ®Google Scholar
• Bondanelli M, Ambrosio MR, Degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4(4):239–249.
   PubMedGoogle Scholar
• Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest. 2002;25(11):971–976.
   PubMed Web of Science ®Google Scholar
• Bol DK, Kiguchi K, Gimenez-Conti I, et al. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene. 1997;14(14):1725–1734.
   PubMed Web of Science ®Google Scholar
• Snibson KJ, Bhathal PS, Hardy CL, et al. High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver. 1999;19(3):242–252.
   PubMedGoogle Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393–1396.
   PubMed Web of Science ®Google Scholar
• Laron Z. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones (Athens). 2008;7(1):24–27.
   PubMedGoogle Scholar
• Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8):2730–2734.
   PubMed Web of Science ®Google Scholar
• Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5): 395–400.
   PubMed Web of Science ®Google Scholar
• Kauppinen-Makelin R, Sane T, Valimaki MJ, et al. Increased cancer incidence in acromegaly–a nationwide survey. Clin Endocrinol (Oxf). 2010;72(2):278–279.
   PubMed Web of Science ®Google Scholar
• Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer. 1991;68(8):1673–1677.
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001;86(7):2929–2934.
   PubMed Web of Science ®Google Scholar
• Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98(4):1466–1475.
   PubMed Web of Science ®Google Scholar
• Sattler MG, van Beek AP, Wolffenbuttel BH, et al. The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone. Radiother Oncol. 2012;104(1):125–130.
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5): 1509–1517.
   PubMed Web of Science ®Google Scholar
• Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.
   PubMed Web of Science ®Google Scholar
• Colao A, Cannavo S, Marzullo P, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148(1):31–38.
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab. 1998;83(6):2121–2125.
   PubMed Web of Science ®Google Scholar
• Claessen KM, Kloppenburg M, Kroon HM, et al. Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res. 2013;23(5):159–164.
   PubMed Web of Science ®Google Scholar
• Claessen KM, Ramautar SR, Pereira AM, et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary. 2014;17(1):44–52.
   PubMed Web of Science ®Google Scholar
• Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235–244.
   PubMed Web of Science ®Google Scholar
• Epstein N, Whelan M, Benjamin V. Acromegaly and spinal stenosis. Case report. J Neurosurg. 1982;56(1):145–147.
   PubMed Web of Science ®Google Scholar
• Kaufman HH, Ommaya AK, Dopman JL, et al. Hypertrophy of the ligamentum flavum. Secondary cord syndrome in an acromegalic. Arch Neurol. 1971;25(3):256–259.
   PubMed Web of Science ®Google Scholar
• Schmidt RF, Goldstein IM, Liu JK. Ossified ligamentum flavum causing spinal cord compression in a patient with acromegaly. J Clin Neurosci. 2013;20(11):1599–1603.
   PubMed Web of Science ®Google Scholar
• Kiss C, Szilagyi M, Paksy A, et al. Risk factors for diffuse idiopathic skeletal hyperostosis: a case-control study. Rheumatology (Oxford). 2002;41(1):27–30.
   PubMed Web of Science ®Google Scholar
• Zak J, Kapitola J, Povysil C, et al. Effect of growth hormone and other hormones on trabecular bone structure in acromegaly. Sb Lek. 1999;100(3):223–233.
   PubMedGoogle Scholar
• Halse J, Melsen F, Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol (Copenh). 1981;97(1):18–22.
   PubMedGoogle Scholar
• Roelfsema F, van der Sluys J, Smeenk D. Quantitation of bone and bone turnover in biopsy specimens from the iliac crest in acromegaly. J Endocrinol. 1970;48(4):lxi.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100(2):384–394.
   PubMed Web of Science ®Google Scholar
• Tamada D, Kitamura T, Onodera T, et al. Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery. Endocr J. 2014;61(3):231–237.
   PubMed Web of Science ®Google Scholar
• Parkinson C, Kassem M, Heickendorff L, et al. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003;88(12):5650–5655.
   PubMed Web of Science ®Google Scholar
• Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol. 2006;155(5):709–715.
   PubMed Web of Science ®Google Scholar
• Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013;98(12):4808–4815.
   PubMed Web of Science ®Google Scholar
• Steinbach HL, Feldman R, Goldberg MB. Acromegaly. Radiology. 1959;72(4):535–549.
   PubMed Web of Science ®Google Scholar
• Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med. 1970;39(153):1–16.
   PubMedGoogle Scholar
• Brody JS, Fisher AB, Gocmen A, et al. Acromegalic pneumonomegaly: lung growth in the adult. J Clin Invest. 1970;49(6):1051–1060.
   PubMed Web of Science ®Google Scholar
• Garcia-Rio F, Pino JM, Diez JJ, et al. Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med. 2001;164(5):852–857.
   PubMed Web of Science ®Google Scholar
• Iandelli I, Gorini M, Duranti R, et al. Respiratory muscle function and control of breathing in patients with acromegaly. Eur Respir J. 1997;10(5): 977–982.
   PubMed Web of Science ®Google Scholar
• Donnelly PM, Grunstein RR, Peat JK, et al. Large lungs and growth hormone: an increased alveolar number? Eur Respir J. 1995;8(6):938–947.
   PubMed Web of Science ®Google Scholar
• Trotman-Dickenson B, Weetman AP, Hughes JM. Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med. 1991;79(290):527–538.
   PubMedGoogle Scholar
• Harrison BD, Millhouse KA, Harrington M, et al. Lung function in acromegaly. Q J Med. 1978;47(188):517–532.
   PubMedGoogle Scholar
• Evans CC, Hipkin LJ, Murray GM. Pulmonary function in acromegaly. Thorax. 1977;32(3):322–327.
   PubMed Web of Science ®Google Scholar
• Lopes AJ, Guedes Da Silva DP, Ferreira AS, et al. What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients? J Phys Ther Sci. 2015;27(3):719–724.
   Web of Science ®Google Scholar
• Grunstein RR, Ho KY, Berthon-Jones M, et al. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med. 1994;150(2):496–502.
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994;121(7):478–483.
   PubMed Web of Science ®Google Scholar
• Davi’ MV, Dalle CL, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533–540.
   PubMed Web of Science ®Google Scholar
• Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 2007;156(3):321–329.
   PubMed Web of Science ®Google Scholar
• Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes. 1982;31(8 Pt 1):663–669.
   PubMed Web of Science ®Google Scholar
• Rosenfeld RG, Wilson DM, Dollar LA, et al. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab. 1982;54(5):1033–1038.
   PubMed Web of Science ®Google Scholar
• Bratusch-Marrain PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab. 1982;55(5):973–982.
   PubMed Web of Science ®Google Scholar
• Costa C, Solanes G, Visa J, et al. Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. Faseb J. 1998;12(14):1455–1460.
   PubMed Web of Science ®Google Scholar
• Boulware SD, Tamborlane WV, Rennert NJ, et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 1994;93(3):1131–1139.
   PubMed Web of Science ®Google Scholar
• Hussain MA, Schmitz O, Mengel A, et al. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest. 1993;92(5):2249–2256.
   PubMed Web of Science ®Google Scholar
• Hansen I, Tsalikian E, Beaufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986;250(3 Pt 1):E269–E273.
   PubMed Web of Science ®Google Scholar
• Foss MC, Saad MJ, Paccola GM, et al. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab. 1991;72(5):1048–1053.
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Bex M, Kamenicky P, et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81–89.
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab. 2013;98(1):E51–E59.
   PubMed Web of Science ®Google Scholar
• Battezzati A, Benedini S, Fattorini A, et al. Insulin action on protein metabolism in acromegalic patients. Am J Physiol Endocrinol Metab. 2003;284(4):E823–E829.
   PubMed Web of Science ®Google Scholar
• Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52(5):549–555.
   PubMed Web of Science ®Google Scholar
• Moller N, Schmitz O, Joorgensen JO, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992;74(5):1012–1019.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Frolich M. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. Clin Endocrinol (Oxf). 1985;22(4):531–537.
   PubMed Web of Science ®Google Scholar
• Mori K, Iwasaki Y, Kawasaki-Ogita Y, et al. Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest. 2013;36(10): 853–859.
   PubMed Web of Science ®Google Scholar
• Kim SK, Suh S, Lee JI, et al. The ability of beta-cells to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients. J Korean Med Sci. 2012;27(2):177–183.
   PubMed Web of Science ®Google Scholar
• Freda PU, Reyes CM, Conwell IM, et al. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab. 2003;88(5):2037–2044.
   PubMed Web of Science ®Google Scholar
• Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol. 2003;148(2):193–201.
   PubMed Web of Science ®Google Scholar
• Wasada T, Aoki K, Sato A, et al. Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J. 1997;44(4):617–620.
   PubMed Web of Science ®Google Scholar
• Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol. 2003;149(6):521–527.
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002;87(9):4142–4146.
   PubMed Web of Science ®Google Scholar
• Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest. 2002;25(6):502–507.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest. 2003;26(6): 533–538.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2014. DOI:10.1007/s11102-014-0585-6.
   Web of Science ®Google Scholar
• Vitale G, Pivonello R, Lombardi G, et al. Cardiovascular complications in acromegaly. Minerva Endocrinol. 2004;29(3):77–88.
   PubMedGoogle Scholar
• Higham CE, Rowles S, Russell-Jones D, et al. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(7):2459–2463.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295): 1754–1759.
   PubMed Web of Science ®Google Scholar
• Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3): 301–342.
   PubMed Web of Science ®Google Scholar
• McCabe J, Ayuk J, Sherlock M. Treatment Factors that Influence Mortality in Acromegaly. Neuroendocrinology. 2015. DOI:10.1159/000375163.
   PubMedGoogle Scholar
• Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189–198.
   PubMed Web of Science ®Google Scholar
• Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(11):4216–4223.
   PubMed Web of Science ®Google Scholar
• Sattler MG, Vroomen PC, Sluiter WJ, et al. Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone. Int J Radiat Oncol Biol Phys. 2013;87(1):53–59.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in. J Clin Endocrinol Metab. 2008;93(1):61–67.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.
   PubMed Web of Science ®Google Scholar
• Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12):4438–4446.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2): 526–529.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11): 3933–3951.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87(9):4054–4058.
   PubMed Web of Science ®Google Scholar
• Guiot G, Bouche J, Hertzog E, et al. Hypophysectomy by trans-sphenoidal route. Ann Radiol (Paris). 1963;6:187–192.
   PubMedGoogle Scholar
• Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15(1):71–83.
   PubMed Web of Science ®Google Scholar
• Fathalla H, Cusimano MD, Di IA, et al. Endoscopic versus microscopic approach for surgical treatment of acromegaly. Neurosurg Rev. 2015;38:541–549.
   PubMed Web of Science ®Google Scholar
• Starke RM, Raper DM, Payne SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190–3198.
   PubMed Web of Science ®Google Scholar
• Dallapiazza RF, Jane JA Jr Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015;44(1):105–115.
   PubMed Web of Science ®Google Scholar
• Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(8):843–849.
   PubMed Web of Science ®Google Scholar
• Goudakos JK, Markou KD, Georgalas C. Endoscopic versus microscopic trans-sphenoidal pituitary surgery: a systematic review and meta-analysis. Clin Otolaryngol. 2011;36(3):212–220.
   PubMed Web of Science ®Google Scholar
• Tabaee A, Anand VK, Barron Y, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg. 2009;111(3):545–554.
   PubMed Web of Science ®Google Scholar
• Cappabianca P, Cavallo LM, Colao A, et al. Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg. 2002;45(4):193–200.
   PubMed Web of Science ®Google Scholar
• Brooke AM, Drake WM. Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary. 2007;10(2):173–179.
   PubMed Web of Science ®Google Scholar
• Dehdashti AR, Ganna A, Karabatsou K, et al. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2008;62(5):1006–1015.
   PubMed Web of Science ®Google Scholar
• Yano S, Kawano T, Kudo M, et al. Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas. Neurol Med Chir (Tokyo). 2009;49(1): 1–7.
   PubMed Web of Science ®Google Scholar
• Campbell PG, Kenning E, Andrews DW, et al. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus. 2010;29(4):E5.
   PubMed Web of Science ®Google Scholar
• Gondim JA, Almeida JP, De Albuquerque LA, et al. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus. 2010;29(4):E7.
   PubMed Web of Science ®Google Scholar
• Hofstetter CP, Mannaa RH, Mubita L, et al. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus. 2010;29(4):E6.
   PubMed Web of Science ®Google Scholar
• Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9): 2732–2740.
   PubMed Web of Science ®Google Scholar
• Wagenmakers MA, Netea-Maier RT, van Lindert EJ, et al. Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormone-secreting macroadenoma. Acta Neurochir (Wien). 2011;153(7):1391–1399.
   PubMed Web of Science ®Google Scholar
• Hazer DB, Isik S, Berker D, et al. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg. 2013;119(6): 1467–1477.
   PubMed Web of Science ®Google Scholar
• van Bunderen CC, van Varsseveld NC, Baayen JC, et al. Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary. 2013;16(2):158–167.
   PubMed Web of Science ®Google Scholar
• Shin SS, Tormenti MJ, Paluzzi A, et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary. 2013;16(4): 435–444.
   PubMed Web of Science ®Google Scholar
• Paluzzi A, Fernandez-Miranda JC, Tonya SS, et al. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17(4):307–319.
   PubMed Web of Science ®Google Scholar
• Yildirim AE, Sahinoglu M, Divanlioglu D, et al. Endoscopic endonasal transsphenoidal treatment for acromegaly: 2010 consensus criteria for remission and predictors of outcomes. Turk Neurosurg. 2014;24(6):906–912.
   PubMed Web of Science ®Google Scholar
• Nishioka H, Fukuhara N, Horiguchi K, et al. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J Neurosurg. 2014;121(3):505–510.
   PubMedGoogle Scholar
• Torales J, Halperin I, Hanzu F, et al. Endoscopic endonasal surgery for pituitary tumors. Results in a series of 121 patients operated at the same center and by the same neurosurgeon. Endocrinol Nutr. 2014;61(8): 410–416.
   PubMedGoogle Scholar
• Bellut D, Hlavica M, Schmid C, et al. Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly. Neurosurg Focus. 2010;29(4):E9.
   PubMed Web of Science ®Google Scholar
• Fahlbusch R, Keller B, Ganslandt O, et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol. 2005;153(2):239–248.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer SM. Intraoperative magnetic resonance imaging during surgery for pituitary adenomas: pros and cons. Endocrine. 2012;42(3):483–495.
   PubMed Web of Science ®Google Scholar
• van den Berg G, van DH, Frolich M, et al. Can intra-operative GH measurement in acromegalic subjects predict completeness of surgery? Clin Endocrinol (Oxf). 1998;49(1):45–51.
   PubMed Web of Science ®Google Scholar
• Abe T, Ludecke DK. Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly. Clin Endocrinol (Oxf). 1999;50(1):27–35.
   PubMed Web of Science ®Google Scholar
• Valdemarsson S, Ljunggren S, Cervin A, et al. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement? Scand J Clin Lab Invest. 2001;61(6): 459–470.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93(8): 2984–2990.
   PubMed Web of Science ®Google Scholar
• Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol. 2001;145(2):137–145.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Bollerslev J, Svartberg J, et al. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol. 2014;171(2):229–235.
   PubMed Web of Science ®Google Scholar
• Hong JW, Ku CR, Kim SH, et al. Characteristics of acromegaly in Korea with a literature review. Endocrinol Metab (Seoul). 2013;28(3):164–168.
   Google Scholar
• Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien). 2005;147(5):485–493.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van DH, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab. 1999;84(10):3551–3555.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu X, Yan Y, et al. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis. Brain Dev. 2015;37(2):181–190.
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8(4): e61523.
   PubMed Web of Science ®Google Scholar
• Frank G, Pasquini E. Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas. Front Horm Res. 2006;34:64–82.
   PubMed Web of Science ®Google Scholar
• Duarte FH, Jallad RS, Bronstein MD. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J Clin Endocrinol Metab. 2015;100:1863–1869. DOI:10.1210/jc.2014-3913.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Goslings BM, Frolich M, et al. The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly. Clin Endocrinol (Oxf). 1979;11(2):235–244.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16): 1171–1177.
   PubMed Web of Science ®Google Scholar
• Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992;21(3):713–735.
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–378.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–1335.
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–4473.
   PubMed Web of Science ®Google Scholar
• Espinosa-de-Los-Monteros AL, Gonzalez B, Vargas G, et al. Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center. Pituitary. 2014. DOI:10.1007/s11102-014-0570-0.
   Web of Science ®Google Scholar
• Giordano C, Ciresi A, Amato MC, et al. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. 2012;15(4):539–551.
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–868.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4): 1397–1403.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331–338.
   PubMed Web of Science ®Google Scholar
• Bandgar TR, Sarathi V, Shivane V, et al. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. J Postgrad Med. 2010;56(1):7–11.
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Miell JP, Chambers SM, et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf). 2005;62(6):742–747.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Pereira AM, Smit JW, et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res. 2005;15(3):200–206.
   PubMed Web of Science ®Google Scholar
• Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf). 2005;62(3):282–288.
   PubMed Web of Science ®Google Scholar
• Lindsay JR, McConnell EM, Hunter SJ, et al. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve ‘safe’ growth hormone levels. Pituitary. 2004;7(3):139–144.
   PubMedGoogle Scholar
• Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18–28.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Galdiero M, et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest. 2008;31(11):956–965.
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151(3):317–324.
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150(4):473–480.
   PubMed Web of Science ®Google Scholar
• Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008;68(3):473–480.
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150(4):489–495.
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuno M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–1833.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Farrall AJ, De BC, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 2014;17(2):132–140.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6): 2781–2789.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11): 875–884.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM, et al. The role of pegvisomant in the treatment of acromegaly. Expert Opin Biol Ther. 2008;8(5):691–704.
   PubMed Web of Science ®Google Scholar
• Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009;161(1):21–25.
   PubMed Web of Science ®Google Scholar
• Jehle S, Reyes CM, Sundeen RE, et al. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(3):1588–1593.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res. 2011;21(3):129–133.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, De Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160(4):529–533.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598–4601.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, De Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99(10):3644–3652.
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97(4):1187–1193.
   PubMed Web of Science ®Google Scholar
• Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4405–4410.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411.
   PubMed Web of Science ®Google Scholar
• Toumanidis ST, Evangelopoulos ME, Ilias I, et al. Is left ventricular dysfunction reversed after treatment of active acromegaly? Pituitary. 2011;14(1):75–79.
   PubMed Web of Science ®Google Scholar
• Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008;31(8): 704–710.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A. Pharmacotherapy for acromegaly: future role for pasireotide? Endocrinol Metab Clin North Am. 2015;44(1):35–41.
   PubMed Web of Science ®Google Scholar
• Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775–783.
   PubMed Web of Science ®Google Scholar
• Breitschaft A, Hu K, Hermosillo RK, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458–465.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Ferreri L, et al. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44(1):89–97.
   PubMed Web of Science ®Google Scholar
• Maione L, Garcia C, Bouchachi A, et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. 2012;97(9):E1714–E1719.
   PubMed Web of Science ®Google Scholar
• Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from acrostudy. Endocr Pract. 2015;21(3):264–274.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. 2015;48(1):334–341.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161(Suppl 1):S3–S10.
   PubMed Web of Science ®Google Scholar
• Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009;161(Suppl 1):S19–S24.
   PubMed Web of Science ®Google Scholar
• Brue T, Castinetti F, Lundgren F, et al. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol. 2009;161(Suppl 1):S11–S17.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–1597.
   PubMed Web of Science ®Google Scholar
• Wass J. Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. Eur J Endocrinol. 2005;152(5):693–694.
   PubMed Web of Science ®Google Scholar
• Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152(1): 61–66.
   PubMed Web of Science ®Google Scholar
• Abu Dabrh AM, Mohammed K, Asi N, et al. Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(11): 4003–4014.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Roelfsema F, Pereira AM, et al. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):223–234.
   PubMedGoogle Scholar
• Resmini E, Murialdo G, Giusti M, et al. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest. 2005;28(2):166–169.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Galdiero M, Grasso LF, et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol. 2010;162(5):993–999.
   PubMed Web of Science ®Google Scholar
• Vilar L, Fleseriu M, Naves LA, et al. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine. 2014;46(3):577–584.
   PubMed Web of Science ®Google Scholar
• Ramirez C, Vargas G, Gonzalez B, et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol. 2012;166(1):21–26.
   PubMed Web of Science ®Google Scholar
• Ozbek M, Erdogan M, Akbal E, et al. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Exp Clin Endocrinol Diabetes. 2009;117(7):309–311.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol. 2008;158(1):19–25.
   PubMed Web of Science ®Google Scholar
• Caron P, Tabarin A, Cogne M, et al. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. Eur J Endocrinol. 2000;142(6):565–571.
   PubMed Web of Science ®Google Scholar
• Livadas S, Hadjidakis DJ, Argyropoulou MI, et al. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens). 2006;5(1):57–63.
   PubMedGoogle Scholar
• Stewart PM, Stewart SE, Clark PM, et al. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf). 1999;50(3):295–299.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–248.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Attanasio R, Verrua E, et al. Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin Endocrinol (Oxf). 2009;71(6):846–852.
   PubMed Web of Science ®Google Scholar
• Wass JA. Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf). 2003;58(2):128–131.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van DH, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476–2482.
   PubMed Web of Science ®Google Scholar
• Solda F, Lumb A, Brada M. Radiotherapy for acromegaly. Wass JAH, editor. Bristol, UK: BioScientifica; 2009. Chapter 10, Acromegaly.
   Google Scholar
• Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2005;62(2): 210–216.
   PubMed Web of Science ®Google Scholar
• Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery. 2008;62(6):1262–1269.
   PubMed Web of Science ®Google Scholar
• Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007;13(7):726–734.
   PubMedGoogle Scholar
• Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics. Neuroendocrinology. 2015. DOI:10.1159/000371819.
   PubMedGoogle Scholar
• Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. 2015;173(4):M85–M97.
   Google Scholar
• Stratakis CA, Matyakhina L, Courkoutsakis N, et al. Pathology and molecular genetics of the pituitary gland in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). Front Horm Res. 2004;32:253–264.
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. Horm Res. 2009;71(Suppl 1):105–111.
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11): E373–E383.
   PubMed Web of Science ®Google Scholar
• Salenave S, Boyce AM, Collins MT, et al. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99(6):1955–1969.
   PubMed Web of Science ®Google Scholar
• Wu Z, Bidlingmaier M, Friess SC, et al. A new nonisotopic, highly sensitive assay for the measurement of human placental growth hormone: development and clinical implications. J Clin Endocrinol Metab. 2003;88(2): 804–811.
   PubMed Web of Science ®Google Scholar
• Cheng V, Faiman C, Kennedy L, et al. Pregnancy and acromegaly: a review. Pituitary. 2012;15(1):59–63.
   PubMed Web of Science ®Google Scholar
• Caron P, Broussaud S, Bertherat J, et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab. 2010;95(10): 4680–4687.
   PubMed Web of Science ®Google Scholar
• Leung KC, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693–721.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Gomez R, Heissler JF, et al. Pregnancy in acromegaly patients treated with pegvisomant. Endocrine. 2015;49(3):769–773.
   Web of Science ®Google Scholar
• Maffei P, Tamagno G, Nardelli GB, et al. Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol (Oxf). 2010;72(5): 668–677.
   PubMed Web of Science ®Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97(7): 2362–2369.
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and Efficacy of Oral Octreotide in Acromegaly: results of a Multicenter Phase III Trial. J Clin Endocrinol Metab. 2015;100(4): 1699–1708.
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Bidlingmaier M, Bailey J, et al. A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans. J Clin Endocrinol Metab. 2010;95(8):3844–3847.
   PubMed Web of Science ®Google Scholar
• Chi C, Du Y, Ye J, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics. 2014;4(11):1072–1084.
   PubMed Web of Science ®Google Scholar
• Sandow N, Klene W, Elbelt U, et al. Intraoperative indocyanine green videoangiography for identification of pituitary adenomas using a microscopic transsphenoidal approach. Pituitary. 2014. DOI:10.1007/s11102-014-0620-7.
   Web of Science ®Google Scholar
• Cruz-Topete D, Christensen B, Sackmann-Sala L, et al. Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity. Eur J Endocrinol. 2011;164(2):157–167.
   PubMed Web of Science ®Google Scholar
• Schmid C, Neidert MC, Tschopp O, et al. Growth hormone and Klotho. J Endocrinol. 2013;219(2):R37–R57.
   PubMed Web of Science ®Google Scholar
• Neidert MC, Sze L, Zwimpfer C, et al. Soluble alpha-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur J Endocrinol. 2013;168(4):575–583.
   PubMed Web of Science ®Google Scholar